Abbvie

ABBV

106.24

+1.60

+1.5%

Please Login or Register

Login|Register FREE

Stock Price
Open: 104.70
Prev. Close: 104.64
Low/Hi: 104.46 - 106.40
52-Week: 59.27 - 104.87
Volumes
Equity: 1,466,910
90-Day Avg: 5,815,303
Option: 12,136
90-Day Avg: 19,711
Volatility
Todays Stock Vol: 22.4
20-Day (HV): 17.4
52-Week (HV): 17.5
30-Day IV: 23.6 -0.7
IV Pct Rank: 93% Elevated
Fundamental
Dividend: 11-Apr $0.71 (Est.)
Div. Yield: 2.7%
Earnings: 26-Jan BMO
P/E Ratio: 25.28
Market Cap: 167.1 B
Short Int Pct: 0.9%
Pct Held By Inst.: 69.0%
Stock Info
Type: Common
Sector: Healthcare
Industry: Drug Manufacturers - Major

ABBV Company Events

Upcoming Events
Event Event Date Location Info
No Upcoming Events
Past Events
Event Event Date Location Info
36th Annual J.P. Morgan Healthcare Conference Jan 10, 11:30 AM
Goldman Sachs 10th Annual Healthcare CEOs Jan 4, 11:00 AM
59th ASH Annual Meeting & Exposition Dec 9, 2017 - Dec 12, 2017
Evercore ISI Biopharma Catalyst/Deep Dive Conference Nov 29, 8:00 AM
Jefferies 2017 London Healthcare Conference Nov 16, 4:20 AM
2017 Credit Suisse Health Care Conference Nov 8, 2017
Liver Meeting 2017 Oct 20, 2017 - Oct 24, 2017
Morgan Stanley 15th Annual Global Health Care Conference Sep 12, 11:10 AM
Goldman Sachs 38th Annual Global Healthcare Conference Jun 13, 11:00 AM
Jefferies 2017 Global Healthcare Conference Jun 8, 2017
53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) Jun 2, 2017 - Jun 6, 2017
UBS Global Healthcare Conference May 22, 8:00 AM
Digestive Disease Week (DDW) 2017 May 6, 2017 - May 9, 2017
Deutsche Bank 42nd Annual Health Care Conference May 3, 8:40 AM
Barclays Global Healthcare Conference Mar 15, 2017
Cowen and Company 37th Annual Health Care Conference Mar 8, 9:20 AM
35th Annual J.P. Morgan Healthcare Conference Jan 11, 11:00 AM
2016 American Society of Hematology Annual Meeting Dec 3, 2016 - Dec 5, 2016 San Diego, CA
i

Data from 25 abstracts evaluating an important variety of investigational uses of the company's portfolio of blood cancer medicines will be presented

Jefferies 2016 London Healthcare Conference Nov 17, 2016
i

Bill Chase, executive vice president and chief financial officer, will participate in a question and answer session at 3:20 AM CT .

25th Annual Credit Suisse Healthcare Conference Nov 8, 1:00 PM
72ndAmerican Society for Reproductive Medicine Scientific Congress & Expo (ASRM), Oct 15, 2016 - Oct 19, 2016
i

New detailed results to be presented on primary and secondary efficacy and safety from two pivotal Phase 3 studies evaluating the use of Elagolix in endometriosis-associated pain - Additional data will be presented on the economic burden of endometriosis and endometriosis-related surgery in women in the United States

AbbVie Presents Data on Eight-Week Treatment of VIEKIRAX Sep 23, 2016
Morgan Stanley Global Healthcare Conference Sep 16, 2016
Morgan Stanley Global Healthcare Conference Sep 14, 2016
Psoriasis 2016 - 5th Congress of the Psoriasis International Network Jul 7, 2016 - Jul 9, 2016
i

will present findings of a Phase 3 study of patients with moderate to severe psoriasis demonstrating that nearly half of adult patients treated with HUMIRA (adalimumab) achieved at least a 75 percent improvement in their moderate to severe fingernail psoriasis compared to patients receiving placebo

Goldman Sachs 37th Annual Global Healthcare Conference Jun 9, 2016
i

Bill Chase, executive vice president and chief financial officer, will participate in a question and answer session at 10:40 AM CT .

Goldman Sachs 37th Annual Global Healthcare Conference Jun 9, 11:40 AM
i

Bill Chase, executive vice president and chief financial officer, will participate in a question and answer session at 10:40 AM CT .

Goldman Sachs Global Healthcare Conference Jun 9, 11:40 AM
Jefferies 2016 Healthcare Conference Jun 8, 2016
i

. Bill Chase, executive vice president and chief financial officer, will participate in a question and answer session at 7:30 AM CT .

AbbVie Inc R&D Day Jun 3, 10:00 AM
American Society of Clinical Oncology (ASCO Jun 3, 2016 - Jun 7, 2016 Chicago
i

present data from studies evaluating Venclexta (venetoclax), a BCL-2 inhibitor being developed by AbbVie and Genentech, a member of the Roche Group, and IMBRUVICA (ibrutinib), an inhibitor of Bruton's tyrosine kinase (BTK), across multiple hematologic malignancies.

UBS Global Health Care Conference May 23, 2016
i

Bill Chase, executive vice president and chief financial officer, will participate in a question and answer session at 1:00 PM CT .

Bank of America Merrill Lynch 2016 Global Health Care Conference May 12, 2016
i

Bill Chase, executive vice president and chief financial officer, will participate in a question and answer session at 1:20 PM CT .

AbbVie Inc Annual Shareholders Meeting May 6, 10:00 AM
Deutsche Bank 41st Annual Health Care Conference May 4, 2016
i

Bill Chase, executive vice president and chief financial officer, will participate in a question and answer session at 9:40 AM CT .

The International Liver Congress (ILC) 2016 Apr 13, 2016 - Apr 17, 2016 Barcelona, Spain
i

25 abstracts have been accepted for presentation. including real-world data that support clinical trial results seen in AbbVie's development program with VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) and EXVIERA (dasabuvir tablets). Abstracts presented will further expand scientific knowledge of VIEKIRAX and EXVIERA in genotype 1 (GT1) and genotype 4 (GT4) chronic hepatitis C virus (HCV) infected patients, including those with compensated cirrhosis (Child-Pugh A). Additionally, data will be presented from AbbVie's HCV pipeline program, investigating its pan-genotypic, once-daily, ribavirin-free regimen of ABT-493 and ABT-530 in patients with genotypes 1-6 (GT1-6) chronic HCV infection, including data on treatment durations of as short as eight weeks in genotypes 1-3 (GT1-3) treatment-nave patients without cirrhosis.

Barclays Global Healthcare Conference Mar 17, 2016
i

Bill Chase, executive vice president and chief financial officer, will participate in a question and answer session at 8 AM CT .

Cowen and Company 36th Annual Health Care Conference Mar 9, 2016
i

Richard A. Gonzalez, chairman and chief executive officer, will participate in a question and answer session at 8:20 AM CT .

Deutsche Bank Pharma One-on-One Day Mar 3, 2016
34th Annual J.P. Morgan Healthcare Conference Jan 13, 2016
i

Richard A. Gonzalez, chairman and chief executive officer, will make a formal presentation on the company at 10:30 AM CT .

57th American Society of Hematology Annual Meeting Dec 5, 2015 - Dec 8, 2015 Orlando, Fla
i

present data from clinical trials evaluating the company's oncology portfolio

Jefferies Autumn 2015 Global Healthcare Conference in London Nov 19, 2015 London
i

Bill Chase, executive vice president and chief financial officer, will participate in a question and answer session at 3:20 AM CT .

Credit Suisse24th Annual Healthcare Conference Nov 11, 12:00 PM
i

Richard A. Gonzalez, chairman and chief executive officer, will participate

European Academy of Dermatology and Venereology (EADV) Congress Oct 7, 2015 Copenhagen, Denmark
Goldman Sachs 36th Annual Global Healthcare Conference Jun 9, 11:00 AM
Goldman Sachs 36th Annual Global Healthcare Conference Jun 9, 11:00 AM
Jefferies 2015 Healthcare Conference Jun 4, 2015
Phase 1 study of ABT-414 mono-or combination therapy with temozolomide (TMZ) in recurrent glioblastoma (GBM); G.K. Hui et al.; Abstract 2016; Jun 1, 1:15 AM
51st Annual Meeting of the American Society of Clinical Oncology May 31, 9:00 AM
Phase 1 interim safety and efficacy of venetoclax (ABT-199/GDC-0199) monotherapy for relapsed/refractory (R/R) multiple myeloma (MM);S. Kumar, et al.; Abstract 8576;Poster May 31, 2015
Phase 1b interim results: venetoclax in combination with bortezomib (BTZ) and dexamethasone (Dex) in R/R MMC. Touzeau, et al.; Abstract 8580;Poster Session May 31, 12:30 PM
Interim results from a dose-escalation study of the BCL-2 inhibitor venetoclax plus bendamustine (B) and rituximab (R) in patients (pts) with R/R NHL; S. de Vos et al.; May 31, 12:30 PM
A randomized Phase 2 study of bortezomib/dexamethasone with or without elotuzumab in patients with relapsed/refractory multiple myeloma May 31, 9:00 AM
Early clinical activity and pharmacodynamic effects of duvelisib, a PI3K-delta,gamma inhibitor, in patients with treatment-naive CLL; Patel et al.; Abstract #7074 May 31, 9:00 AM
51st Annual Meeting of the American Society of Clinical Oncology (ASCO), May 29, 2015
UBS Global Healthcare Conference May 20, 2015
Digestive Disease Week (DDW) 201 May 16, 2015
i

May 16 – 19, in Washington, D.C 18 abstracts in its gastroenterology and hepatology programs will be presen

Bank of America Merrill Lynch 2015 Health Care Conference May 13, 4:00 PM
Deutsche Bank 40th Annual Health Care Conference May 6, 2015
51st American Society of Clinical Oncology (ASCO)
2015 Morgan Stanley Global Healthcare Conference 8:45 AM
i

Bill Chase, executive vice president and chief financial officer, will participate

Wait, Before You Leave...

Want to Know More About ABBV Earnings?

Receive your FREE email to get Wall Street expected earnings moves and daily upcoming earnings alerts!
Market Chameleon